Published in Breast Cancer Res on May 14, 2012
Circulating cell-free miRNAs as biomarker for triple-negative breast cancer. Br J Cancer (2015) 1.09
Unraveling 50-Year-Old Clues Linking Neurodegeneration and Cancer to Cycad Toxins: Are microRNAs Common Mediators? Front Genet (2012) 0.92
The induction of microRNA-16 in colon cancer cells by protein arginine deiminase inhibition causes a p53-dependent cell cycle arrest. PLoS One (2013) 0.91
Overexpression of microRNA-200c predicts poor outcome in patients with PR-negative breast cancer. PLoS One (2014) 0.90
Simultaneously expressed miR-424 and miR-381 synergistically suppress the proliferation and survival of renal cancer cells---Cdc2 activity is up-regulated by targeting WEE1. Clinics (Sao Paulo) (2013) 0.90
A multi-targeted approach to suppress tumor-promoting inflammation. Semin Cancer Biol (2015) 0.87
Stat3 regulates ErbB-2 expression and co-opts ErbB-2 nuclear function to induce miR-21 expression, PDCD4 downregulation and breast cancer metastasis. Oncogene (2015) 0.87
Attenuation of microRNA-16 derepresses the cyclins D1, D2 and E1 to provoke cardiomyocyte hypertrophy. J Cell Mol Med (2015) 0.85
MicroRNAs in breast cancer: oncogene and tumor suppressors with clinical potential. J Zhejiang Univ Sci B (2015) 0.84
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res (2013) 0.83
MicroRNA-218 is upregulated in gastric cancer after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy and increases chemosensitivity to cisplatin. World J Gastroenterol (2014) 0.82
MiR-16 mediates trastuzumab and lapatinib response in ErbB-2-positive breast and gastric cancer via its novel targets CCNJ and FUBP1. Oncogene (2016) 0.80
The oncomiR miR-197 is a novel prognostic indicator for non-small cell lung cancer patients. Br J Cancer (2015) 0.80
Targeting ErbB-2 nuclear localization and function inhibits breast cancer growth and overcomes trastuzumab resistance. Oncogene (2014) 0.79
MicroRNA-16 sensitizes breast cancer cells to paclitaxel through suppression of IKBKB expression. Oncotarget (2016) 0.79
Inhibition of miR301 enhances Akt-mediated cell proliferation by accumulation of PTEN in nucleus and its effects on cell-cycle regulatory proteins. Oncotarget (2016) 0.78
Roles of mitochondrial transcription factor A and microRNA‑590‑3p in the development of colon cancer. Mol Med Rep (2016) 0.77
Identification of Reliable Reference Genes for Quantification of MicroRNAs in Serum Samples of Sulfur Mustard-Exposed Veterans. Cell J (2015) 0.77
Reconstruction of temporal activity of microRNAs from gene expression data in breast cancer cell line. BMC Genomics (2015) 0.76
MicroRNA-16 modulates HuR regulation of cyclin E1 in breast cancer cells. Int J Mol Sci (2015) 0.76
Regulation of steroid hormone receptors and coregulators during the cell cycle highlights potential novel function in addition to roles as transcription factors. Nucl Recept Signal (2016) 0.75
MicroRNA-711 is a prognostic factor for poor overall survival and has an oncogenic role in breast cancer. Oncol Lett (2016) 0.75
Suppression of microRNA-16 protects against acute myocardial infarction by reversing beta2-adrenergic receptor down-regulation in rats. Oncotarget (2017) 0.75
ApoptomiRs of Breast Cancer: Basics to Clinics. Front Genet (2016) 0.75
Deregulation of the miR-16-KRAS axis promotes colorectal cancer. Sci Rep (2016) 0.75
MicroRNA-206 is differentially expressed in Brca1-deficient mice and regulates epithelial and stromal cell compartments of the mouse mammary gland. Oncogenesis (2016) 0.75
Breast-related effects of selective estrogen receptor modulators and tissue-selective estrogen complexes. Breast Cancer Res (2014) 0.75
Determination of absolute expression profiles using multiplexed miRNA analysis. PLoS One (2017) 0.75
MicroRNA Expression in Malignant Pleural Mesothelioma and Asbestosis: A Pilot Study. Dis Markers (2017) 0.75
Identification of reference miRNAs in plasma useful for the study of oestrogen-responsive miRNAs associated with acquired Protein S deficiency in pregnancy. BMC Res Notes (2017) 0.75
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial. JAMA (2002) 80.37
MicroRNA signatures in human cancers. Nat Rev Cancer (2006) 46.29
TM4: a free, open-source system for microarray data management and analysis. Biotechniques (2003) 38.02
Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci U S A (2002) 32.26
Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science (1989) 31.55
MicroRNA gene expression deregulation in human breast cancer. Cancer Res (2005) 27.56
Tumour invasion and metastasis initiated by microRNA-10b in breast cancer. Nature (2007) 21.53
miR-15 and miR-16 induce apoptosis by targeting BCL2. Proc Natl Acad Sci U S A (2005) 21.51
Endogenous human microRNAs that suppress breast cancer metastasis. Nature (2008) 14.37
Widespread microRNA repression by Myc contributes to tumorigenesis. Nat Genet (2007) 10.78
microRNAs as oncogenes and tumor suppressors. Dev Biol (2006) 10.68
Influence of estrogen plus progestin on breast cancer and mammography in healthy postmenopausal women: the Women's Health Initiative Randomized Trial. JAMA (2003) 10.61
miRecords: an integrated resource for microRNA-target interactions. Nucleic Acids Res (2008) 8.97
Cyclin E and survival in patients with breast cancer. N Engl J Med (2002) 6.44
The miR-15a-miR-16-1 cluster controls prostate cancer by targeting multiple oncogenic activities. Nat Med (2008) 5.74
Breast cancer after use of estrogen plus progestin in postmenopausal women. N Engl J Med (2009) 4.80
The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell (2010) 4.71
Progesterone induces adult mammary stem cell expansion. Nature (2010) 4.69
Coordinate suppression of ERBB2 and ERBB3 by enforced expression of micro-RNA miR-125a or miR-125b. J Biol Chem (2006) 4.59
MicroRNA-221/222 confers tamoxifen resistance in breast cancer by targeting p27Kip1. J Biol Chem (2008) 4.56
A hierarchical network of interreceptor interactions determines signal transduction by Neu differentiation factor/neuregulin and epidermal growth factor. Mol Cell Biol (1996) 4.47
MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A (2008) 4.33
Retracted MicroRNA-221/222 negatively regulates estrogen receptor alpha and is associated with tamoxifen resistance in breast cancer. J Biol Chem (2008) 3.63
Prevention of Brca1-mediated mammary tumorigenesis in mice by a progesterone antagonist. Science (2006) 3.26
Differential gene regulation by the two progesterone receptor isoforms in human breast cancer cells. J Biol Chem (2001) 3.07
Systemic delivery of synthetic microRNA-16 inhibits the growth of metastatic prostate tumors via downregulation of multiple cell-cycle genes. Mol Ther (2009) 2.92
MicroRNA signatures predict oestrogen receptor, progesterone receptor and HER2/neu receptor status in breast cancer. Breast Cancer Res (2009) 2.59
Activation of the Src/p21ras/Erk pathway by progesterone receptor via cross-talk with estrogen receptor. EMBO J (1998) 2.58
microRNA-205 regulates HER3 in human breast cancer. Cancer Res (2009) 2.53
Progesterone receptor contains a proline-rich motif that directly interacts with SH3 domains and activates c-Src family tyrosine kinases. Mol Cell (2001) 2.44
miR-15a and miR-16 are implicated in cell cycle regulation in a Rb-dependent manner and are frequently deleted or down-regulated in non-small cell lung cancer. Cancer Res (2009) 2.39
c-Myc in breast cancer. Endocr Relat Cancer (2000) 2.32
Estradiol-regulated microRNAs control estradiol response in breast cancer cells. Nucleic Acids Res (2009) 2.27
Genomic profiling of microRNAs and messenger RNAs reveals hormonal regulation in microRNA expression in human endometrium. Biol Reprod (2009) 2.26
Retracted Differential expression of microRNAs in myometrium and leiomyomas and regulation by ovarian steroids. J Cell Mol Med (2007) 2.24
Knockdown of STAT3 expression by RNA interference inhibits the induction of breast tumors in immunocompetent mice. Cancer Res (2005) 2.20
Cyclin E amplification/overexpression is a mechanism of trastuzumab resistance in HER2+ breast cancer patients. Proc Natl Acad Sci U S A (2011) 2.18
Regulation of signal transduction pathways by estrogen and progesterone. Annu Rev Physiol (2005) 2.17
SnapShot: MicroRNAs in Cancer. Cell (2009) 2.10
Antagonist-occupied human progesterone B-receptors activate transcription without binding to progesterone response elements and are dominantly inhibited by A-receptors. Mol Endocrinol (1993) 1.78
miR-22 inhibits estrogen signaling by directly targeting the estrogen receptor alpha mRNA. Mol Cell Biol (2009) 1.70
MiR-15a and MiR-16 control Bmi-1 expression in ovarian cancer. Cancer Res (2009) 1.64
Biphasic regulation of breast cancer cell growth by progesterone: role of the cyclin-dependent kinase inhibitors, p21 and p27(Kip1). Mol Endocrinol (1997) 1.62
Heregulin is sufficient for the promotion of tumorigenicity and metastasis of breast cancer cells in vivo. Mol Cancer Res (2003) 1.58
Myc: Maestro of MicroRNAs. Genes Cancer (2010) 1.58
Up-regulation of miR-21 by HER2/neu signaling promotes cell invasion. J Biol Chem (2009) 1.53
Oncogenic HER2{Delta}16 suppresses miR-15a/16 and deregulates BCL-2 to promote endocrine resistance of breast tumors. Carcinogenesis (2010) 1.42
Oncogenic Wip1 phosphatase is inhibited by miR-16 in the DNA damage signaling pathway. Cancer Res (2010) 1.37
Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. Mol Endocrinol (1999) 1.34
Myc represses miR-15a/miR-16-1 expression through recruitment of HDAC3 in mantle cell and other non-Hodgkin B-cell lymphomas. Oncogene (2011) 1.33
Progestin-dependent progression of human breast tumor xenografts: a novel model for evaluating antitumor therapeutics. Cancer Res (2007) 1.31
Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. Mol Cell Biol (1991) 1.30
miRNA-34a is associated with docetaxel resistance in human breast cancer cells. Breast Cancer Res Treat (2011) 1.29
NDF/heregulin induces persistence of terminal end buds and adenocarcinomas in the mammary glands of transgenic mice. Oncogene (1996) 1.27
Estrogen and progestin regulation of cell cycle progression. J Mammary Gland Biol Neoplasia (1998) 1.26
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol (2005) 1.25
DLEU2, frequently deleted in malignancy, functions as a critical host gene of the cell cycle inhibitory microRNAs miR-15a and miR-16-1. Exp Cell Res (2009) 1.22
TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res (2007) 1.19
Progesterone involvement in breast development and tumorigenesis--as revealed by progesterone receptor "knockout" and "knockin" mouse models. Steroids (2003) 1.19
c-Myb oncoprotein is an essential target of the dleu2 tumor suppressor microRNA cluster. Cancer Biol Ther (2008) 1.15
Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol (2007) 1.12
Activation of ErbB-2 via a hierarchical interaction between ErbB-2 and type I insulin-like growth factor receptor in mammary tumor cells. Oncogene (2001) 1.12
ErbB2-mediated Src and signal transducer and activator of transcription 3 activation leads to transcriptional up-regulation of p21Cip1 and chemoresistance in breast cancer cells. Mol Cancer Res (2009) 1.09
Cyclin E deregulation is an early event in the development of breast cancer. Breast Cancer Res Treat (2008) 1.08
Progesterone facilitates chromosome instability (aneuploidy) in p53 null normal mammary epithelial cells. FASEB J (2000) 1.06
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol (2010) 1.06
Low molecular weight cyclin E is specific in breast cancer and is associated with mechanisms of tumor progression. Cell Cycle (2009) 1.06
Steroid receptor and microRNA regulation in cancer. Curr Opin Oncol (2010) 1.04
Progestin effects on long-term growth, death, and Bcl-xL in breast cancer cells. Biochem Biophys Res Commun (2000) 1.03
Induction of cell proliferation and survival genes by estradiol-repressed microRNAs in breast cancer cells. BMC Cancer (2012) 1.02
A sequence in the 5' flanking region confers progestin responsiveness on the human c-myc gene. J Steroid Biochem Mol Biol (1997) 1.02
Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res (2010) 1.01
Down-regulation of the cyclin E1 oncogene expression by microRNA-16-1 induces cell cycle arrest in human cancer cells. BMB Rep (2009) 1.01
The progesterone receptor hinge region regulates the kinetics of transcriptional responses through acetylation, phosphorylation, and nuclear retention. Mol Endocrinol (2010) 1.01
Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res (2011) 1.01
The MPA mouse breast cancer model: evidence for a role of progesterone receptors in breast cancer. Endocr Relat Cancer (2009) 0.99
Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol (2008) 0.97
Cyclin E and p16 immunoreactivity in epithelioid trophoblastic tumor--an aid in differential diagnosis. Am J Surg Pathol (2006) 0.95
Identification and biochemical characterization of Rap2C, a new member of the Rap family of small GTP-binding proteins. Biochimie (2005) 0.93
Steroid receptors and microRNAs: relationships revealed. Steroids (2010) 0.93
Progestin regulated miRNAs that mediate progesterone receptor action in breast cancer. Mol Cell Endocrinol (2012) 0.92
Progestin-induced caveolin-1 expression mediates breast cancer cell proliferation. Oncogene (2006) 0.92
The incidence of breast cancer and changes in the use of hormone replacement therapy: a review of the evidence. Maturitas (2009) 0.91
Synthetic progestins induce growth and metastasis of BT-474 human breast cancer xenografts in nude mice. Menopause (2010) 0.91
Interactions between progestins and heregulin (HRG) signaling pathways: HRG acts as mediator of progestins proliferative effects in mouse mammary adenocarcinomas. Oncogene (1999) 0.89
MicroRNAs in cancer: personalizing diagnosis and therapy. Ann N Y Acad Sci (2010) 0.88
Postmenopausal hormone replacement therapy: effects on normal mammary gland in humans and in a mouse postmenopausal model. J Mammary Gland Biol Neoplasia (2002) 0.88
Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat (2009) 0.87
Involvement of matrix metalloproteinase activity in hormone-induced mammary tumor regression. Am J Pathol (2006) 0.87
Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. Steroids (2010) 0.82
Hormone dependence of a mouse mammary tumor line induced in vivo by medroxyprogesterone acetate. Breast Cancer Res Treat (1990) 0.80
Mechanisms of cell cycle arrest in response to TGF-beta in progestin-dependent and -independent growth of mammary tumors. Exp Cell Res (2001) 0.76
Isolating human transcription factor targets by coupling chromatin immunoprecipitation and CpG island microarray analysis. Genes Dev (2002) 6.74
Gene silencing in cancer by histone H3 lysine 27 trimethylation independent of promoter DNA methylation. Nat Genet (2008) 5.08
Methylation-specific oligonucleotide microarray: a new potential for high-throughput methylation analysis. Genome Res (2002) 2.71
Methyl-CpG binding proteins identify novel sites of epigenetic inactivation in human cancer. EMBO J (2003) 2.21
Genetic unmasking of epigenetically silenced tumor suppressor genes in colon cancer cells deficient in DNA methyltransferases. Hum Mol Genet (2003) 1.93
Methylation microarray analysis of late-stage ovarian carcinomas distinguishes progression-free survival in patients and identifies candidate epigenetic markers. Clin Cancer Res (2002) 1.91
Genistein alters methylation patterns in mice. J Nutr (2002) 1.60
Methylation target array for rapid analysis of CpG island hypermethylation in multiple tissue genomes. Am J Pathol (2003) 1.51
Applications of CpG island microarrays for high-throughput analysis of DNA methylation. J Nutr (2002) 1.46
Differential distribution of DNA methylation within the RASSF1A CpG island in breast cancer. Cancer Res (2003) 1.45
Chromatin immunoprecipitation microarrays for identification of genes silenced by histone H3 lysine 9 methylation. Proc Natl Acad Sci U S A (2004) 1.45
Triple analysis of the cancer epigenome: an integrated microarray system for assessing gene expression, DNA methylation, and histone acetylation. Cancer Res (2003) 1.38
Canonical and atypical E2Fs regulate the mammalian endocycle. Nat Cell Biol (2012) 1.37
High-fat or ethinyl-oestradiol intake during pregnancy increases mammary cancer risk in several generations of offspring. Nat Commun (2012) 1.35
Double RNA interference of DNMT3b and DNMT1 enhances DNA demethylation and gene reactivation. Cancer Res (2003) 1.32
Single-cell analysis of circulating tumor cells identifies cumulative expression patterns of EMT-related genes in metastatic prostate cancer. Prostate (2012) 1.28
Oligonucleotide-based microarray for DNA methylation analysis: principles and applications. J Cell Biochem (2003) 1.26
Progestins induce transcriptional activation of signal transducer and activator of transcription 3 (Stat3) via a Jak- and Src-dependent mechanism in breast cancer cells. Mol Cell Biol (2005) 1.25
Epigenetic silencing of the protocadherin family member PCDH-gamma-A11 in astrocytomas. Neoplasia (2005) 1.24
TNF alpha acting on TNFR1 promotes breast cancer growth via p42/P44 MAPK, JNK, Akt and NF-kappa B-dependent pathways. Exp Cell Res (2007) 1.19
Promoter hypermethylation of FBXO32, a novel TGF-beta/SMAD4 target gene and tumor suppressor, is associated with poor prognosis in human ovarian cancer. Lab Invest (2010) 1.17
Quantitative assessment of DNA methylation: Potential applications for disease diagnosis, classification, and prognosis in clinical settings. J Mol Med (Berl) (2006) 1.16
Heregulin induces transcriptional activation of the progesterone receptor by a mechanism that requires functional ErbB-2 and mitogen-activated protein kinase activation in breast cancer cells. Mol Cell Biol (2003) 1.14
Epigenetic silencing mediated through activated PI3K/AKT signaling in breast cancer. Cancer Res (2011) 1.13
Progestin effects on breast cancer cell proliferation, proteases activation, and in vivo development of metastatic phenotype all depend on progesterone receptor capacity to activate cytoplasmic signaling pathways. Mol Endocrinol (2007) 1.12
Modulation of genetic and epigenetic biomarkers of colorectal cancer in humans by black raspberries: a phase I pilot study. Clin Cancer Res (2010) 1.12
Serum hepatitis B surface antigen concentration correlates with HBV DNA level in patients with chronic hepatitis B. Antivir Ther (2010) 1.10
Epigenetic gene silencing in cancer initiation and progression. Cancer Lett (2003) 1.08
Aberrant transforming growth factor beta1 signaling and SMAD4 nuclear translocation confer epigenetic repression of ADAM19 in ovarian cancer. Neoplasia (2008) 1.08
CMS: a web-based system for visualization and analysis of genome-wide methylation data of human cancers. PLoS One (2013) 1.07
Progesterone receptor induces ErbB-2 nuclear translocation to promote breast cancer growth via a novel transcriptional effect: ErbB-2 function as a coactivator of Stat3. Mol Cell Biol (2010) 1.06
A genetic screen identifies interferon-α effector genes required to suppress hepatitis C virus replication. Gastroenterology (2013) 1.06
Promoter region methylation and reduced expression of thrombospondin-1 after oxygen-glucose deprivation in murine cerebral endothelial cells. J Cereb Blood Flow Metab (2006) 1.04
Hypomethylation and aberrant expression of the glioma pathogenesis-related 1 gene in Wilms tumors. Neoplasia (2007) 1.03
Differential contributory roles of nucleotide excision and homologous recombination repair for enhancing cisplatin sensitivity in human ovarian cancer cells. Mol Cancer (2011) 1.02
Epigenetic hypothesis tests for methylation and acetylation in a triple microarray system. J Comput Biol (2005) 1.01
Epigenetic influences of low-dose bisphenol A in primary human breast epithelial cells. Toxicol Appl Pharmacol (2010) 0.99
Promoter hypomethylation of EpCAM-regulated bone morphogenetic protein gene family in recurrent endometrial cancer. Clin Cancer Res (2013) 0.99
Effect of host and viral factors on hepatitis B e antigen-positive chronic hepatitis B patients receiving pegylated interferon-α-2a therapy. Antivir Ther (2011) 0.99
Expressed CpG island sequence tag microarray for dual screening of DNA hypermethylation and gene silencing in cancer cells. Cancer Res (2002) 0.99
Activation of Stat3 by heregulin/ErbB-2 through the co-option of progesterone receptor signaling drives breast cancer growth. Mol Cell Biol (2008) 0.97
Comprehensive methylome analysis of ovarian tumors reveals hedgehog signaling pathway regulators as prognostic DNA methylation biomarkers. Epigenetics (2013) 0.96
Differential methylation hybridization using CpG island arrays. Methods Mol Biol (2002) 0.95
Differential methylation hybridization array of endometrial cancers reveals two novel cancer-specific methylation markers. Clin Cancer Res (2007) 0.94
Aberrant TGFβ/SMAD4 signaling contributes to epigenetic silencing of a putative tumor suppressor, RunX1T1 in ovarian cancer. Epigenetics (2011) 0.92
Black raspberry-derived anthocyanins demethylate tumor suppressor genes through the inhibition of DNMT1 and DNMT3B in colon cancer cells. Nutr Cancer (2013) 0.92
Conjugated linoleic acid induces apoptosis through estrogen receptor alpha in human breast tissue. BMC Cancer (2008) 0.91
Ribosomal DNA methylation in patients with endometrial carcinoma: an independent prognostic marker. Cancer (2002) 0.90
Heregulin inhibits proliferation via ERKs and phosphatidyl-inositol 3-kinase activation but regulates urokinase plasminogen activator independently of these pathways in metastatic mammary tumor cells. Int J Cancer (2002) 0.89
Preprocessing differential methylation hybridization microarray data. BioData Min (2011) 0.89
Delta1-pyrroline-5-carboxylic acid formed by proline dehydrogenase from the Bacillus subtilis ssp. natto expressed in Escherichia coli as a precursor for 2-acetyl-1-pyrroline. J Agric Food Chem (2007) 0.88
An empirical Bayes model for gene expression and methylation profiles in antiestrogen resistant breast cancer. BMC Med Genomics (2010) 0.88
Function and regulatory mechanisms of the candidate tumor suppressor receptor protein tyrosine phosphatase gamma (PTPRG) in breast cancer cells. Anticancer Res (2010) 0.88
Transactivation of ErbB-2 induced by tumor necrosis factor alpha promotes NF-kappaB activation and breast cancer cell proliferation. Breast Cancer Res Treat (2009) 0.87
Aberrant DNA methylation profile and frequent methylation of KLK10 and OXGR1 genes in hepatocellular carcinoma. Genes Chromosomes Cancer (2009) 0.86
p42/p44 MAPK-mediated Stat3Ser727 phosphorylation is required for progestin-induced full activation of Stat3 and breast cancer growth. Endocr Relat Cancer (2013) 0.86
Integrated analysis identifies a class of androgen-responsive genes regulated by short combinatorial long-range mechanism facilitated by CTCF. Nucleic Acids Res (2012) 0.86
Identifying hypermethylated CpG islands using a quantile regression model. BMC Bioinformatics (2011) 0.84
Effectiveness of a government-organized and hospital-initiated treatment for multidrug-resistant tuberculosis patients--a retrospective cohort study. PLoS One (2013) 0.84
Epigenetic deregulation of the anaplastic lymphoma kinase gene modulates mesenchymal characteristics of oral squamous cell carcinomas. Carcinogenesis (2013) 0.84
Chloroquine eliminates cancer stem cells through deregulation of Jak2 and DNMT1. Stem Cells (2014) 0.84
Keratinocyte growth factor (KGF) induces tamoxifen (Tam) resistance in human breast cancer MCF-7 cells. Anticancer Res (2006) 0.84
Methylation-specific oligonucleotide microarray. Methods Mol Biol (2004) 0.83
Progesterone receptor assembly of a transcriptional complex along with activator protein 1, signal transducer and activator of transcription 3 and ErbB-2 governs breast cancer growth and predicts response to endocrine therapy. Breast Cancer Res (2013) 0.83
Polymorphisms and Plasma Levels of Tissue Inhibitor of Metalloproteinase-3: Impact on Genetic Susceptibility and Clinical Outcome of Oral Cancer. Medicine (Baltimore) (2015) 0.82
Induction of apoptosis by (-)-gossypol-enriched cottonseed oil in human breast cancer cells. Int J Mol Med (2010) 0.82
Novel role of signal transducer and activator of transcription 3 as a progesterone receptor coactivator in breast cancer. Steroids (2010) 0.82
Black raspberries protectively regulate methylation of Wnt pathway genes in precancerous colon tissue. Cancer Prev Res (Phila) (2013) 0.82
Modulation of multidrug resistance gene expression in human breast cancer cells by (-)-gossypol-enriched cottonseed oil. Anticancer Res (2007) 0.81
Comparing multiple ChIP-sequencing experiments. J Bioinform Comput Biol (2011) 0.81
Small interfering RNA targeted to IGF-IR delays tumor growth and induces proinflammatory cytokines in a mouse breast cancer model. PLoS One (2012) 0.81
Targeting Stat3 induces senescence in tumor cells and elicits prophylactic and therapeutic immune responses against breast cancer growth mediated by NK cells and CD4+ T cells. J Immunol (2012) 0.80
Clinical relevance of ErbB-2/HER2 nuclear expression in breast cancer. BMC Cancer (2012) 0.80
Cancer epigenetics: a perspective on the role of DNA methylation in acquired endocrine resistance. Chin J Cancer (2011) 0.80
Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids (2012) 0.79
Primary cultured human breast epithelial cells up-regulate protein disulfide isomerase in response to zeranol. Anticancer Res (2007) 0.79
Conjugated linoleic acid (CLA) modulates prostaglandin E2 (PGE2) signaling in canine mammary cells. Anticancer Res (2006) 0.79
Emerging methods for analysis of the cancer methylome. Pharmacogenomics (2008) 0.79
Esophagogastric varices predict mortality in hospitalized patients with alcoholic liver disease in Taiwan. Hepatogastroenterology (2010) 0.79
Involvement of TGF-beta(s)/T(beta)Rs system in tumor progression of murine mammary adenocarcinomas. Breast Cancer Res Treat (2003) 0.78
Complications of alcoholic liver cirrhosis: active assessment by endoscopy and sonography. Hepatology (2010) 0.78
Conjugated linoleic acid (CLA) up-regulates the estrogen-regulated cancer suppressor gene, protein tyrosine phosphatase gamma (PTPgama), in human breast cells. Anticancer Res (2006) 0.78
Humic acid induces oxidative DNA damage, growth retardation, and apoptosis in human primary fibroblasts. Exp Biol Med (Maywood) (2003) 0.78